RESULTS	At 52 weeks , canagliflozin 300 mg demonstrated noninferiority and , in a subsequent assessment , showed superiority to sitagliptin 100 mg in reducing A1C ( -1.03 % [ -11.3 mmol/mol ] and -0.66 % [ -7.2 mmol/mol ] , respectively ; least squares mean difference between groups , -0.37 % [ 95 % CI , -0.50 to -0.25 ] or -4.0 mmol/mol [ -5.5 to -2.7 ] ) .\